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Protocol for a randomized controlled trial of the Breaking Free Online Health and Justice program 1 
for substance misuse in prison settings 2 
 3 
Abstract 4 
Background: Substance misuse, including problematic drug and alcohol use, are significant issues in 5 
society that can have multiple detrimental effects. Many people access support for their substance 6 
misuse during prison sentences, due to the associations between substance misuse and offending, 7 
and the high proportion of the prison population who have drug and alcohol issues. Breaking Free 8 
Online Health and Justice is a computer-assisted therapy program that has been developed to support 9 
substance-involved offenders to address their substance misuse and associated offending within 10 
prison settings. Methods: This will be a parallel-group randomized controlled trial of 4-week Breaking 11 
Free Online Health and Justice program as an adjunct to standard treatment for substance misuse, in 12 
comparison to standard treatment only, in a male Category D open prison. Interventional and control 13 
groups will be compared in terms of the changes in their scores on multiple measures from baseline 14 
to post-treatment assessment at4-weeks, and then 3- and 6-months follow-up. Participants will be 15 
adult male offenders serving sentences in prison in England who have demonstrable difficulties with 16 
drugs and/or alcohol for at least the past 12-months. The primary outcome measure will be self-17 
reported substance misuse, with secondary outcomes being standardized psychometric assessments 18 
of substance dependence, mental health, biopsychosocial functioning, quality of life and post-release 19 
offending. Other secondary measures will include frequency of completion of specific intervention 20 
strategies in the program. Discussion: This study will examine whether Breaking Free Online Health 21 
and Justice as an adjunct to standard substance misuse interventions in prisons, improves outcomes 22 
for substance-involved offenders receiving interventions in custodial settings. Findings from the study 23 
will be used to inform further developments of the program and potential improvements to custodial 24 
treatment. 25 
 26 








Substance misuse, including problematic drug and alcohol use, are significant issues in society that 6 
can have multiple detrimental effects. Substance misuse is implicated in a number of criminal 7 
offences, including acquisitive crime (Comiskey, Stapleton, & Kelly, 2012; Hayhurst et al., 2013), anti-8 
social and violent behavior (Boden, Fergusson, & Horwood, 2012; Lundholm, Haggård, Möller, 9 
Hallqvist, & Thiblin, 2013), domestic and intimate partner violence (Stuart et al., 2008; Wilson, 10 
Graham, & Taft, 2017) and child neglect (Solis, Shadur, Burns, & Hussong, 2012). Links between 11 
substance use and criminal behavior are identified within the research literature (Bennett, Holloway, 12 
& Farrington, 2008; Hough, 2002; Schroeder, Giordano, & Cernkovich, 2007). Levels of crime reported 13 
by substance users during periods of use (Ball, Shaffer, & Nurco, 1983; Bennett & Holloway, 2009; 14 
Bennett et al., 2008; Best, Sidwell, Gossop, Harris, & Strang, 2001; Goldstein, 1985; Gossop, Marsden, 15 
Stewart, & Rolfe, 2000; Inciardi, 1979; McGlothlin, Anglin, & Wilson, 1978), and the high proportion 16 
of the prison population who are substance misusers (Budd, Collier, Mhlanga, Sharp, & Weir, 2005; 17 
Jones et al., 2007; Phillips, 2000; Young, Wells, & Gudjonsson, 2011) all indicate that substance misuse 18 
and offending often co-occur and that substance misuse is a primary “criminogenic” factor (Weekes, 19 
Moser, & Langevin, 1999).   20 
 21 
In the 2016 Crime Survey for England and Wales, 8.4% of 16 – 59 year old participants living in the UK 22 
reported using an illicit drug within the last 12-months, which, if representative, would extrapolate to 23 
approximately 2.7 million people (Home Office, 2016). The economic costs to society of substance 24 
misuse are substantial, with problematic alcohol misuse alone being estimated to have cost £ 47 billion 25 
in 2016 (PHE, 2016). Recent data reported by Public Health England from the National Drug Treatment 26 
Monitoring System demonstrate that overall, 279,793 adults were in contact with drug and alcohol 27 
 3 
 
services between 2016 and 2017 (PHE, 2017), with 26% of those receiving treatment for opiate 1 
dependence being referred into treatment by criminal justice services. Furthermore, up to 48% of 2 
those seeking treatment for both opiate and ‘novel psychoactive substance’ dependence were 3 
referred via the criminal justice system (PHE, 2017). And additionally, a recent systematic review 4 
which included studies from multiple countries, found that both alcohol use disorder and substance 5 
use disorder are highly prevalent amongst the prison population, with pooled prevalence estimates 6 
of each being 24% and 51% respectively (Fazel, Yoon, & Hayes, 2017).    7 
 8 
Given the significant associations between substance use and offending, it seems intuitive that if any 9 
intervention for substance-involved offenders is to be effective, it needs to address not only the 10 
substance use but also the offending behavior that may be associated with it (Elison, Davies, et al., 11 
2017). In order to meet this requirement, Breaking Free Online (BFO) Health and Justice, a computer-12 
assisted therapy (CAT) program designed to address both substance misuse and offending behaviors 13 
simultaneously, has been developed. Such CAT approaches have the potential to widen access to 14 
evidence-based treatment for substance misusing individuals as they can be delivered at scale, and 15 
because intervention content is delivered via a computer in a highly standardized way, CAT can 16 
enhance  treatment fidelity and thus treatment effectiveness (Bickel, Marsch, Buchhalter, & Badger, 17 
2008; Moore, Fazzino, Garnet, Cutter, & Barry, 2011).  18 
 19 
This criminal-justice specific version of BFO has been developed via modification of a version of the 20 
program that has been delivered in community-based substance misuse treatment settings for the 21 
past eight-years. Published research informed by guidance by the UK Medical Research Council (MRC) 22 
around the development and evaluation of complex interventions (Craig et al., 2008; Moore et al., 23 
2015) has examined the evidence-base underpinning the clinical content of BFO (Dugdale, Ward, et 24 
al., 2016), and barriers and facilitators of the implementation of the program in real-world treatment 25 
settings (Dugdale, Elison, Davies, Ward, & Dalton, 2017; Dugdale, Elison, Ward, Davies, & Dalton, 2016; 26 
Elison, Ward, Davies, & Moody, 2014; Ward, Davies, Dugdale, Elison, & Bijral, 2017). Research 27 
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examining the effectiveness of the program (Elison, Davies, & Ward, 2015a, 2015b; Elison, Ward, 1 
Davies, Lidbetter, et al., 2014; Elison, Ward, et al., 2017) has demonstrated significant reductions in 2 
substance dependence and use, and significant improvements in mental health and broader 3 
psychosocial functioning. Examination of the mechanisms of action of BFO has demonstrated that 4 
users follow tailoring advice provided by the program, that the program exhibits a ‘dose-response’, 5 
and that completion of cognitive restructuring strategies in the program underpins changes to broader 6 
biopsychosocial functioning (Elison, Jones, Ward, Dugdale, & Davies, 2017).  7 
 8 
Since 2015 BFO has been available in prisons in addition to community settings via the ‘Virtual 9 
Campus’ (VC), the UK prisons IT infrastructure that allows offenders to access a limited range of online 10 
programs to support their education, training and employment. However, BFO has become the first 11 
healthcare program to be included on VC, and the first digital intervention for offenders to be 12 
accredited by the Ministry of Justice Correctional Services Advice and Accreditation Panel. Mixed-13 
methods research conducted by the authors explored both the barriers and facilitators of 14 
implementation of BFO in prison settings (Elison, Weston, Davies, Dugdale, & Ward, 2015; Elison, 15 
Weston, Dugdale, Ward, & Davies, 2016), and also examined clinical outcomes for offenders accessing 16 
the program as part of the ‘Gateways’ through-care initiative (Davies et al., 2017), which aimed to 17 
support substance-involved offenders as they transition back to the community.  18 
 19 
Qualitative interview data from 16 offenders engaging with BFO and 10 members of prison staff 20 
supporting them suggested that both offenders and staff were able to overcome initial anxieties about 21 
using digital technology. Offenders reported the program supported them to develop coping skills to 22 
enable them to remain abstinent from using drugs and alcohol, and therefore reduce their chances of 23 
reoffending when they were released (Elison, Weston, et al., 2015). Staff reported that they felt the 24 
program provided an opportunity for offenders to access an evidence-based intervention to allow 25 
them to work on their drug and alcohol difficulties, and also provided an opportunity to use the VC in 26 
a novel way to further support offender rehabilitation (Davies et al., 2017). Analyses of quantitative 27 
 5 
 
clinical outcomes from a sample of 151 male offenders accessing BFO before being released from 1 
prison (Davies et al., 2017; Elison, Weston, et al., 2015), demonstrated significant reductions in alcohol 2 
and drug dependence and consumption, significant improvements in quality of life, and significant 3 
improvements in multiple aspects of broader biopsychosocial functioning. However, only within-4 
subject analyses were conducted in this research, with no ‘standard treatment’ control group having 5 




This study will evaluate, via a randomized controlled trial (RCT) methodology, the efficacy of BFO 10 
within a criminal justice population. The principle aim of this study is to determine the effectiveness 11 
of BFO when delivered alongside standard treatment, compared to standard treatment only, in 12 
reducing alcohol and drug consumption and dependence, and any possible impact on mental health 13 
and broader biopsychosocial functioning. It is anticipated that delivery of BFO alongside standard 14 
treatment should confer some added benefits to participants engaging with this novel intervention, 15 
when compared to participants engaging with standard treatment only. This means there may be 16 
some post-treatment differences between the two study groups in terms of substance-related 17 
outcomes and broader biopsychosocial functioning.  18 
 19 
Design 20 
This will be a randomized, parallel-group longitudinal comparison study of 4-week periods of either i) 21 
BFO plus standard treatment, or ii) standard treatment only, using intention to treat (ITT) analyses to 22 
examine outcomes.  23 
 24 
Setting 25 
The study will be conducted in an adult male prison in North-West England, UK. This prison is a 26 
‘Category D’ open prison where offenders are, subject to approval, provided with ‘Release on 27 
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Temporary License’ (ROTL) where they are granted release to work in the community or have ‘home 1 
leave’. This prison is a resettlement prison which has an operational capacity of just over 600 male 2 
offenders, approximately a quarter of whom are either on life sentences or subject to indeterminate 3 
sentences. Approximately, 75% of the men in the prison are serving sentences of 4-years or longer at 4 
any one time. Around three-quarters of the men in the prison are over the age of 30 years, and around 5 
40% have identified substance misuse difficulties. The prison places a strong emphasis on 6 
rehabilitation and community reintegration, running a range of vocational training courses, alongside 7 
initiatives to support the men serving sentences in the prison to maintain and enhance the 8 
relationships they have with their families.  9 
 10 
This category of prison has been chosen for the study because, although even the very highest security 11 
prisons in the UK have significant issues with drug and alcohol use, offenders in a Category D prison 12 
may potentially have the most opportunity to use substances, as they spend some of their time in the 13 
community. Most participants may be on ROTL during the study, including resettlement day release, 14 
and resettlement overnight release, so it is more likely that outcomes related to substance use will be 15 
an artifact of treatment effects, rather than lack of opportunity to use substances due to incarceration 16 
in a highly secure environment. Although it is anticipated that most, if not all, participants will be 17 
receiving ROTL during the study, the ROTL status of each participant will be recorded during their first 18 
treatment session and this will be taken into account during data analyses, if there are a significant 19 
number of participants not provided with ROTL during the study. Participants will be recruited from 20 
standard alcohol and drug misuse services in the prison, which are delivered in coordination with Her 21 
Majesty’s Prison and Probation Service (HMPPS).  22 
 23 
Participants 24 
Participants included in the study will be offenders currently serving a prison sentence aged 18 to 65 25 
years with problem alcohol and/or drug use of duration of 12-months or longer. This period of time is 26 
in line with DSM-V criteria for substance related disorders (American Psychiatric Association, 2000). It 27 
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is estimated that a total of 240 participants will need to be recruited and screened in order to obtain 1 
a sample of 120 evaluable participants (see ‘Power Calculation’). 2 
 3 
- Inclusion criteria  4 
1. Male offenders currently serving a prison sentence with problem alcohol and/or drug use aged 5 
18 to 65 years. 6 
2. Willing and able to give informed consent for participation in the study. 7 
3. Has at least 4-months left to serve of their sentence at the prison acting as the research site, 8 
at the time they are recruited to the study. 9 
4. Problem alcohol and/or drug use present for more than 12-months. 10 
5. Willing to follow a treatment for problem alcohol and/or drug use for 4-weeks. 11 
6. Willing to provide outcome measures at 3- and 6-months follow-up. 12 
7. Concomitant alcohol and drug/s use permitted, as well as any prescribed medication. 13 
 14 
- Exclusion Criteria 15 
1. Participation in any other alcohol and/or drug related clinical studies.  16 
2. Participant receiving standard treatment for alcohol and/or drug misuse at the time of 17 
recruitment into the study. 18 
3. Individuals detained under the Mental Health Act. 19 
4. Individuals with a known and diagnosed intellectual or developmental disability.  20 




Breaking Free Online Health and Justice 25 
 8 
 
BFO is an online treatment program for substance-involved offenders. Clinical content of BFO has been 1 
informed by the available evidence-base around effective biopsychosocial and behavioral intervention 2 
approaches for addressing drug and alcohol misuse (National Treatment Agency for Substance Misuse, 3 
2006a, 2006b; NICE, 2007, 2011, 2012), including cognitive-behavioral principles (Beck, 1993; Beck, 4 
Wright, Newman, & Liese, 2011), and other approaches including mindfulness-based relapse 5 
prevention (Marlatt, Bowen, Chawla, & Witkiewitz, 2010; Marlatt & Donovan, 2005).  6 
 7 
When an individual first uses BFO, they complete a psychometric assessment developed by the 8 
authors, the ‘Recovery Progression Measure’ (RPM: Elison, Davies, & Ward, 2016), which is contained 9 
within the program. The RPM measures baseline levels of functioning, and treatment-related changes 10 
in functioning, across six domains; ‘negative thoughts’, ‘emotional impact’, ‘unhelpful behaviors’, 11 
‘difficult situations’, ‘physical sensations’, and ‘lifestyle’. Date generated via completion of the RPM is 12 
then utilized by the BFO program to populate a visual depiction of a six-domain biopsychosocial model, 13 
the ‘Lifestyle Balance Model’ (LBM: Davies, Elison, Ward, & Laudet, 2015), which forms the theoretical 14 
underpinnings of the program and is based on the five-factor model used in cognitive behavioral 15 
therapy (Greenberger & Padesky, 1995; Williams & Chellingsworth, 2010). The LBM (see Figure 1) acts 16 
as a clinical formulation to help the user understand the domains of their functioning that may be 17 
implicated in their substance misuse. 18 
 19 
Based on RPM scores, each of the six domains of the visual depiction of the LBM are colored either 20 
green, amber or red. This ‘traffic light’ system indicate respectively, ‘little’, ‘moderate’ or ‘significant’ 21 
impairment in each of the six domains. Tailored advice then guides the user to concentrate on 22 
completing intervention strategies contained in the program that are aligned to domains of 23 
functioning in the LBM where they may be experiencing the greatest levels of impairment (amber and 24 
red domains of the LBM). However, users are also encouraged to complete and interventions within 25 




Table 1 provides an overview of the clinical content of BFO and the theoretical underpinnings of 1 
individual intervention strategies within the program. Table 1 maps the clinical content of BFO onto 2 
individual behavior change techniques (BCTs) from the BCT taxonomy (V1) (Dugdale, Ward, et al., 3 
2016; Michie, Hyder, Walia, & West, 2011). The BCT taxonomy (V1) provides a standardized means of 4 
describing the clinical content of complex behavioral change interventions (Michie et al., 2011). 5 
 6 
TABLE 1 HERE 7 
 8 
The BFO program has been designed to be used by individuals as either a stand-alone or adjunct 9 
treatment program alongside standard treatment, and as either self-help or as CAT with support by 10 
practitioners, keyworkers, peer-mentors or other supporters. Consultation with HMPPS has ensured 11 
that all intervention strategies in the program are appropriate for the prison setting and comply with 12 
HMPPS quality assurance, security and information assurance processes. For this study, the BFO 13 
program will be comprised of 8 sessions which will be run over 4-weeks, with two sessions held each 14 
week. 15 
 16 
Standard treatment 17 
Both study groups will receive standard treatment as part of the study design. It is expected that there 18 
will be a degree of heterogeneity within both the BFO and control groups in terms of the ‘standard 19 
treatment’ each participant receives. Information regarding the specific standard treatments each 20 
participant receives will be collected, including the specific standard treatments each participant 21 
receives, the number of sessions completed, what kind of practitioner has delivered it, and also the 22 
medications each participant may have been prescribed during the course of the study (see Appendix 23 
B). These data will allow comparisons to be made between different control treatments. 24 
 25 
In terms of the psychosocial and behavioral support treatments available in prisons, low-intensity 26 
group-based interventions are usually delivered by key-workers in alcohol and drug misuse services 27 
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and include techniques such as motivational interviewing and contingency management. These group-1 
based interventions will be delivered with groups of participants that are of a similar size to the group 2 
sessions of BFO, i.e. groups of 10 participants. In order to avoid violation of the stable unit treatment 3 
value assumption, participants in the BFO group will receive their group-based standard treatment in 4 
groups that are run separately from the group-based standard treatments the control group receive.   5 
 6 
More formal psychological therapies are usually delivered by specialist psychological therapists 7 
through CBT based interventions and are delivered on a one-to-one basis. All standard treatment 8 
sessions have a duration range of 30-60 min and take place once or twice a week for a period of 9 
approximately 4 – 12 weeks. The number of interventions each participant will receive may vary. 10 
During treatment concomitant alcohol and drug/s use may be permitted, as well as any prescribed 11 
medication (detoxification included).  12 
 13 
Procedure 14 
Site investigators and practitioners working in the prison substance misuse service will inform 15 
participants of the study. Site investigators will be responsible for completing screening, consent and 16 
randomization. Site investigators and practitioners will be responsible for conducting baseline and 4-17 
week post-baseline assessments. Practitioners will be responsible for delivering both BFO and the 18 
standard treatments received by the two study groups. Site investigators will be responsible for 19 
conducting 3- and 6-month follow-up assessments. All site investigators and practitioners have been 20 
vetted and security cleared to work in prisons by HMPPS and have enhanced clearance via the UK 21 
Government Disclosure Barring Service. The site investigators have trained all participating 22 
practitioners in delivering BFO as CAT and have also conducted training around RCT methodology. All 23 
practitioners are trained and experienced facilitators of structured substance misuse interventions. 24 
Both site investigators and practitioners have received training in ethics and confidentiality issues 25 




All prospective participants that potentially meet the study criteria will be informed of the study’s 1 
objectives and requirements using the Participant Information Sheet and Informed Consent Form 2 
before any screening procedures are performed. If willing to participate in the study, participants will 3 
be requested to provide written consent after being given sufficient time to consider their 4 
participation and having had the opportunity to ask for further details. The Informed Consent Form 5 
will be signed and dated by both the participant and the site investigator. The participant will be 6 
provided with a copy of the signed consent form and the Participant Information Sheet. The original 7 
consent forms will be retained in a secure storage facility separately from source data to protect 8 
against breach of privacy and participant anonymity in terms of outcomes. 9 
 10 
If written consent is given, each participant will then be randomized to either the BFO or control group.  11 
Randomization will occur at the level of the individual participants, with participants being assigned 12 
to one of the study groups following the generation of a random allocation sequence via the Research 13 
Randomizer (from the Social Psychology Network- Urbaniak & Plous, 2011). Sequentially-numbered 14 
opaque sealed envelopes containing the treatment group that the participant will be allocated to will 15 
be delivered to the research site prior to commencement of the study. The participant number will be 16 
determined according to the order of enrolment in the study. The site investigator will assign and open 17 
one sealed envelope per participant. 18 
  19 
Following randomization, all participants will be required to complete an assessment with the site 20 
investigator to assess study eligibility. A screening log, including the participant number and treatment 21 
group assigned by randomization and any subsequent reason/s for exclusion from the study (if 22 
applicable), will then be completed by the site investigator.  23 
 24 
No longer than 2-weeks after being randomized and completing the eligibility screening, both study 25 
groups will complete a battery of assessments to collect data around primary and secondary outcomes 26 
and demographic information including age and ethnicity. This battery of assessment will be delivered 27 
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digitally via desktop computers within the prison IT suites. The assessment for the BFO group will be 1 
completed within the BFO program. The control group will complete the measures via a specially 2 
developed digital assessment platform which will deliver the same assessment that is included in the 3 
BFO program, but without providing access to any of the digital intervention content provided by BFO. 4 
 5 
Study groups will then complete a period of 4-weeks of substance misuse treatment, of either i) BFO 6 
plus standard treatment, or ii) standard treatment only. For the BFO group, the 4-week intervention 7 
will be delivered to groups of approximately 10 participants at a time, so it is estimated that 8 
approximately 6 – 8 groups will need to run successively in order to achieve the sample size required, 9 
in order to account for some attrition between baseline and 4-week post-treatment assessments. BFO 10 
group participants will receive two sessions of BFO each week, alongside any standard treatment they 11 
may be engaging with. 12 
 13 
Online access to the BFO program is granted via the activation of an access code given to the 14 
participant at the alcohol and drug misuse service by authorized practitioners. To activate the access 15 
card and create a personal account, the participant must enter a user name and password of his choice 16 
along with the access code. The practitioners will be able to assist with the online access if required. 17 
The participants must also agree to the Terms & Conditions of using BFO, which are in accordance 18 
with the Participant Information Sheet and Informed Consent Form and conform to the European 19 
Union General Data Protection Regulation around the use of digitally captured personal data. The 20 
practitioners must ensure that they log out of BFO at the end of each treatment session to protect the 21 
confidentiality of the data. 22 
 23 
Procedures to enhance retention of participants during the 4-week treatment period will include 24 
practitioners providing ongoing support during weekly key-working sessions, which all offenders in 25 
the prison will routinely receive during the standard substance misuse treatment. When participants 26 
do dropout of the study, new participants will be recruited and randomized to replace dropouts, in 27 
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order to ensure the required sample size of 120 participants (60 per group) complete the 4-week 1 
treatment period and provide post-treatment data. However, in line with ITT principles, all 2 
randomized participants, including dropouts, will be included in the final analyses (see ‘Data Analysis’ 3 
section). After completion of the 4-week treatment period, participants in both groups will complete 4 
the same battery of digital psychometric assessments on the prison desktop computers.  5 
 6 
Follow-up assessments will then also be completed at 3- and 6-months post-treatment with all 7 
participants. Follow-up assessments may be completed either in the community if offenders have 8 
been released, or in prison if they are still serving their sentence. Depending on participants’ 9 
preference, the site investigators will contact all participants who have been released back to the 10 
community via telephone or email, and their assessment will be completed either over the phone, or 11 
via a link to an online version of the assessment. For those participants who are still serving a prison 12 
sentence or have been reconvicted and are serving a new sentence, they will be visited by the site 13 
investigator at their current prison and their follow-up assessment will be completed there.  14 
 15 
By following the procedure described above, each participant will take part in the study for a total of 16 
approximately 7-months, including 4-weeks of treatment and 3- and 6-month follow-up assessments. 17 
It is likely that the study will run for a total of approximately 18-months, which will include enough 18 
time for recruitment, running enough successive 4-week long BFO groups to achieve the required 19 
sample size, and completion of all 3- and 6-month follow-up assessments. 20 
 21 
Measures 22 
The primary outcome will be self-reported substance use which will be calculated using answers to 23 
two questions i) ‘in the last week, how many (unit of measurement) of (substance) did you use on a 24 
typical day?’, and ii) ‘in a typical week, how many days are you using (substance)?’. Given the research 25 
setting, i.e. a Category D ‘open prison’ where offenders spend time in the community each week, it is 26 
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more likely that any substance use outcomes will be due to genuine treatment effects, than they 1 
would be in a more highly secure prison setting with fewer opportunities to access and use substances.  2 
 3 
A number of secondary outcomes will also be measured and will come from standardized 4 
psychometric assessments of biopsychosocial functioning, which will include:  5 
i) Severity of substance dependence: This will be measured using the Severity of Dependence 6 
Scale (SDS;  Gossop et al., 1995), which is a 5-item, 4-point Likert scale measuring psychological 7 
dependence on illicit drugs, that has been previously used in studies of persistent drug use in 8 
prison populations (Strang et al., 2006) and studies of programs to address substance related 9 
offending behaviors (Crane & Blud, 2012). It has been demonstrated to have excellent 10 
reliability with an alpha coefficient of .89. 11 
 12 
ii) Mental health sequelae: This will be measured using the Patient Health Questionnaire (PHQ-13 
4; Kroenke, Spitzer, Williams, & Löwe, 2009), which is a 4-item, 4-point Likert scale measuring 14 
depression and anxiety, which has been demonstrated to have excellent internal reliability 15 
(alpha = .81), with scores on the PHQ-4 having been demonstrated to converge with scores 16 
on other measures of anxiety and the 20-Item Short Form Health Survey. 17 
 18 
iii) Quality of life: This will be measured using 5 items from the World Health Organization Quality 19 
of life measure (WHOQoL-BREF; Skevington, Lotfy, & O'Connell, 2004): A total of 5 items 20 
(items 1, 2, 17, 18, 20) from the WHOQoL-BREF have been selected for measuring general 21 
quality of life (QoL). Taken as a whole measure, the WHOQoL-BREF is a 26-item, 5-point Likert 22 
scale containing items measuring 4 main domains - physical, psychological, social and 23 
environmental life satisfaction. As only the first 5 items of the WHOQoL-BREF are being used, 24 
internal/external reliability and concurrent validity analyses will be conducted on data 25 




iv) Biopsychosocial functioning: This will be measured using the Recovery Progression Measure 1 
(RPM; Elison, Davies, et al., 2016; Elison, Dugdale, Ward, & Davies, 2017), which is a 36-item 2 
measure comprising 6 ‘impact slider’, 11-point Likert scale items each measuring level of 3 
severity of impairment in the following 6 domains of functioning; difficult situations, negative 4 
thoughts, emotions, unhelpful behaviors, physical sensations, lifestyle. In addition, the RPM 5 
contains 30 dichotomous ‘yes/no’ response items measuring presence or absence of specific 6 
biopsychosocial issues within each of the 6 domains. Statistical standardization analyses based 7 
on a sample of 2218 service users seeking support for substance misuse found the overall RPM 8 
scale to have excellent reliability with an alpha coefficient of .89. The RPM has also been found 9 
to be a valid measure with scores from 9208 service users converging significantly with those 10 
on standardized psychometric measures of mental health and substance dependence (p < 11 
.0001). 12 
 13 
In addition to the standardized measures described above, socio-demographic data will also be 14 
collected via the digital assessment completed by both study groups, including age and ethnicity. 15 
Additional socio-demographic data will be collected via paper/pen assessment when participants are 16 
first randomized, including educational level achieved, employment status before entering prison, and 17 
marital status (See Appendix A), and what standard treatments each participant has received (see 18 
Appendix B). This will allow comparisons of the two study groups to be made, and also comparisons 19 
of all participants with the broader prison population.  20 
 21 
When follow-up assessments are conducted at 3- and 6-months, each offender will also be asked 22 
about any further involvement with criminal justice authorities since being released from prison, if 23 
they have been released from prison in the interim, and if so, the nature of this involvement with the 24 
authorities, e.g. being arrested, any court appearances etc. (See Appendix C). For ethical and legal 25 
reasons, these questions will be restricted to questions that enquire as to criminal justice system 26 
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involvement only, as opposed to asking participants about any crimes they may have committed that 1 
may not have been discovered by the authorities.  2 
 3 
Data analysis 4 
Quantitative data will be analyzed and reported using SPSS® Version 25.0 (or later) with all analyses 5 
to be performed as per the statistical analysis plan. The appropriate 95% - confidence interval will be 6 
applied. The all-randomized population will consist of all participants in the study that have completed 7 
the Screening Visit and have been allocated to either the i) BFO plus standard treatment, or, ii) 8 
standard treatment only group. The per-protocol population will consist of all participants randomized 9 
into the study who have completed the 4-week treatment period as well as all follow-up assessments.  10 
 11 
Interim and final analyses will be performed on the basis of an ITT population, with the all-randomized 12 
population included in the analyses. No participants will be excluded from the ITT analyses, i.e. those 13 
who have withdrawn, been lost to follow-up, or have provided incomplete outcomes data. Separate 14 
analyses will also be conducted on the per-protocol population who have provided at least one set of 15 
follow-up data. Outcomes from these two analyses (ITT, per-protocol population) will be compared to 16 
examine whether missing data may have had an impact on reliability of conclusions formed around 17 
comparative effectiveness of the two study conditions (i. BFO plus standard treatment, ii. Standard 18 
treatment only. 19 
 20 
Previous analyses (Elison, Davies, et al., 2015a, 2015b; Elison, Weston, et al., 2015) indicate that data 21 
will likely be non-normally distributed in which case nonparametric Analyses of Covariance (ANCOVA) 22 
using appropriate distribution such as Poisson distribution, will be used to compare the study groups 23 
at 4-weeks post-treatment and 3- and 6-months follow-up on self-reported substance use, substance 24 
dependence, mental health sequelae, biopsychosocial functioning and quality of life. However, 25 
normality will be tested when data are available for analyses, and appropriate distributions will be 26 
applied. Specialist statistical support will be sought from colleagues at one of the collaborating 27 
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academic institutions (University of Manchester). When analyzing differences between the two study 1 
groups at each of the outcomes data time-points, (4-weeks post-treatment, 3- and 6-month follow-2 
ups) baseline scores will be controlled for as post-treatment between-group differences may reflect 3 
both treatment effects and also group differences at baseline that randomization may not have 4 
addressed. Differences between the groups in post-treatment scores will be ascertained using 5 
estimated marginal means.  6 
 7 
Effect sizes will also be calculated to examine robustness of between-group differences and within-8 
group changes over time, using partial eta squared (ὴ2), which is an appropriate measure of effect size 9 
for ANCOVA. The numbers of participants fulfilling clinical threshold scores for substance dependence, 10 
depression and anxiety at baseline and post-treatment will also be examined.  11 
 12 
Interim analyses will be performed on the first 30 participants of each group to have completed the 13 
3- and 6-months follow-up after treatment completion. Attrition in each study group and equivalence 14 
of study group characteristics at baseline will be taken into account, in addition to outcomes in order 15 
to ascertain whether there are significant differences between the two groups at the study mid-point. 16 
An interim report will be issued prior to completion of the study and a final report will be issued and 17 
submitted to the ethics committee within 6-months of completion of the study. 18 
 19 
Power calculation 20 
Since the study is a parallel-group comparison, equal numbers of participants will be required for each 21 
of the groups; i) BFO plus standard treatment, and, ii) standard treatment only. The study projection 22 
of the sample size will require 60 evaluable participants in each treatment group to achieve enough 23 
power (assuming power of 0.80 with α = .05) with an allowance of 50% attrition at 3- and 6-months 24 
follow-up, which is in line with previous studies with offender populations receiving interventions for 25 
substance misuse in correctional settings (e.g. Crisanti, Case, Isakson, & Steadman, 2014). In addition, 26 
this level of attrition is also seen in substance misuse intervention research more generally (e.g. 27 
 18 
 
Brorson, Ajo Arnevik, Rand-Hendriksen, & Duckert, 2013) and in many digital interventions studies 1 
(e.g. Eysenbach, 2005). To obtain a total of 120 evaluable participants, it is estimated 240 participants 2 
will need to be recruited and screened. The sample size may be recalculated after an interim analysis 3 
when data for 30 evaluable participants per treatment group are available.  4 
 5 
These estimations have been based on previous samples used for assessments of CAT (Carroll et al., 6 
2008), some of which have used longitudinal statistical analyses (Koski-Jännes, Cunningham, & 7 
Tolonen, 2009; Kypri, Langley, Saunders, Cashell-Smith, & Herbison, 2008). It is envisaged that the 8 
estimated evaluable participant population will be sufficiently large to enable meaningful descriptive 9 
comparisons to be performed. However, these participation numbers may be subject to alterations 10 
depending on the interim analyses which will be performed. 11 
 12 
Discussion 13 
This protocol describes the methodology for an RCT to examine the efficacy of a CAT program for 14 
substance-involved offenders, Breaking Free Online (BFO) Health and Justice, when delivered 15 
alongside standard treatment, compared with standard treatment only, in a prison setting. This 16 
program is the first digital offender management program to be accredited and commissioned by the 17 
UK Ministry of Justice, and to date, this is the first RCT of a digital treatment program for offenders to 18 
be conducted within the UK prison estate. 19 
 20 
Published research examining effectiveness of both the community treatment setting version of the 21 
program (Elison, Davies, et al., 2015a, 2015b) and the criminal justice setting version described in this 22 
protocol (Davies et al., 2017; Elison, Weston, et al., 2015) has suggested that the program may be 23 
effective in supporting substance misusing individuals to significantly reduce their substance use and 24 
dependence. In addition, the program may significantly reduce the severity of mental health 25 
difficulties and biopsychosocial impairment and improve quality of life (Elison, Ward, Davies, 26 




Other published research has examined mechanisms of action of BFO in a sample of participants 2 
engaging with the program in community-based treatment settings (Elison, Jones, et al., 2017), which 3 
has demonstrated the primacy of cognitive change to instigating behavioral change. Completion of 4 
cognitive restructuring strategies in the program has been demonstrated to be associated with 5 
multiple aspects of behavioral and biopsychosocial improvements. In addition, this research has 6 
demonstrated that individuals using BFO follow tailoring advice provided by the program, which 7 
suggests that users spend more time working on intervention strategies associated with domains of 8 
biopsychosocial functioning that they might be experiencing greater levels of impairment. Therefore, 9 
for the group in this RCT who will be engaging with BFO alongside standard treatment, the 10 
mechanisms of action analyses conducted will be replicated, to examine the mechanisms of action of 11 
the program when implemented in criminal justice settings.  12 
 13 
Potential limitations of the methodology include the fact that it will be difficult for the investigators 14 
or the practitioners working in the prison substance misuse service to be blinded to the allocation of 15 
participants to each of the two study groups. This is because the investigators will have to randomize 16 
participants and then organize the BFO groups in the prison, and so they will need to know which 17 
group each participant is randomized to in order to do this. Although the practitioners will not 18 
immediately know which group each participant has been allocated to, very shortly after 19 
randomization they will receive a list of all offenders in the BFO group. This is because they will need 20 
to check attendance to the group, which is particularly important in a secure prison environment in 21 
which the whereabouts of individual offenders must be accounted for at all times. It is also a 22 
requirement of prison regimes in the UK for any member of staff facilitating a group session to know 23 
ahead of the session which offenders will be attending. This is so staff can be aware ahead of the 24 
session of any special circumstances surrounding each offender that may need to be taken into 25 
account or may pose a risk for any reason, for example if a specific offender had recently had any 26 




Another limitation lies in the fact that the level of randomization is at the level of individual offenders, 2 
which means that intervention group participants and control group participants will have the 3 
opportunity to interact with one another within the prison. This may result in members of the 4 
intervention group discussing content of BFO with control group participants, which may contaminate 5 
the outcomes and violate the stable unit treatment value assumption. However, this study has to be 6 
conducted in a very specific kind of prison environment, which limited the number of potential 7 
research sites and made the option of randomization at the level of the research site impractical. 8 
Indeed, recruiting prisons to participate in research is difficult generally, given the unique challenges 9 
faced within such secure environments and the additional challenges posed by issues such as 10 
understaffing in most UK prisons – this makes it difficult for prisons to participate in additional 11 
activities outside of the core prison regime. And from a methodological perspective, the study has to 12 
be conducted in an open prison where participants may conceivably have an opportunity to continue 13 
to use substances, although the authors note there is still significant illicit substance use in the UK and 14 
other countries, even in high-secure prisons.  15 
 16 
Finally, a significant limitation may lie with the possible attrition rates that may be expected from a 17 
study that includes substance-involved offenders as participants, as it can be particularly difficult to 18 
maintain engagement with individuals who may have issues around substance misuse and offending. 19 
Although measures can be put in place to enhance retention of participants whilst they are still serving 20 
their prison sentence, such as weekly key-working sessions with practitioners as part of standard 21 
treatment, it may be particularly challenging to retain participants in the study once they are released 22 
back to the community. Every attempt will be made to contact participants and obtain follow-up data, 23 
and it is hoped that as most participants will be in contact with probation services, this may provide a 24 







ANCOVA - analysis of covariance; ANOVA - analysis of variance; CAT - computer-assisted therapy; CBT 3 
- cognitive-behavioural therapy; HMPPS - Her Majesty's Prison and Probation Service; ITT - intention 4 
to treat; LBM - Lifestyle Balance Model; NICE - National Institute of Health and Care Excellence; PHQ - 5 
Patient Health Questionnaire; QoL - quality of life; RCT - randomised controlled trial; RPM - Recovery 6 
Progression Measure; SDS - Severity of Dependence Scale; VC - Virtual Campus; WHOQoL-BREF - 7 
World Health Organisation Quality of Life Scale. 8 
 9 
Ethics approval and consent to participate 10 
Ethical approval for an amended version of this protocol, for which ethical approval had already been 11 
granted, was granted by the North West – Greater Manchester West Research Ethics Committee on 12 
30.08.2017 (REC Ref: 17/NW/0422). Participants must have provided informed consent, via reading 13 
the Participant Information Sheet and signing the Consent Form, before they can take part in the 14 
study. 15 
 16 
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 19 
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Requests for anonymised datasets and access to the materials contained within Breaking Free Online 21 
Health and Justice will be considered upon request in writing to the authors. 22 
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Table 1: Breaking Free Online content  1 
 2 
Strategies included in 
Breaking Free Online    
Description of strategy   Therapeutic approaches underpinning 
strategies 
BCT taxonomy (V1) techniques (number in taxonomy) 
Lifestyle balance model 
(individualized diagram) 
Generic formulation; Idiosyncratic 
formulation; Personalized feedback; Case 
formulation – understand the links between 
situations, thoughts, emotions, behaviors, 
physical sensations and lifestyle 
Node-link mapping (International 
Treatment Effectiveness Program (ITEP); 
Cognitive-behavioral therapy (CBT)  
Information about antecedents (4.2); Information about health 
consequences (5.1); Salience of consequences (5.2); Information 
about social and environmental consequences (5.3); Information 
about emotional consequences (5.6) 
Understanding your 
difficult situations  
 
Assessment; Self-monitoring; Standardized 
measures; Psycho-education on impact of 
problematic situations; Intervention to help 
people in distress access support 
All structured therapeutic approaches; 
Psycho-education; Guided self-help  
Social support (unspecified) (3.1); Reduce negative emotions (11.2) 
Managing your risky 
situations: Recognize– 
avoid–cope 
Recognize–avoid–cope; Relapse prevention 
for coping with 
environmental/situational/emotional 
triggers; Creating action plans on how to 
avoid or cope in high risk situations 
Relapse prevention; Refusal skills  Problem solving (1.2); Action planning (1.4); Instruction on how to 
perform a behavior (4.1); Behavioral practice/rehearsal (8.1); 
Behaviour substitution (8.2); Avoidance/reducing exposure to cues 
for the behavior (12.3); Goal setting (behavior) (1.1); Problem 
solving (1.2); Action planning (1.4) 
Understanding your 
negative thoughts  
Psycho-education on impact on negative 
thoughts  
Psycho-education; Guided self-help  Information about antecedents (4.2); Information about health 
consequences (5.1); Salience of consequences (5.2); Information 
about social and environmental consequences (5.3); Information 
about emotional consequences (5.6) 
Escaping your mind traps  Mind traps; Cognitive restructuring; 
Challenge thoughts that may be unhelpful 
International Treatment Effectiveness 
Program (ITEP); Cognitive-behavioral 
therapy (CBT)  
Re-attribution (4.3); Framing-reframing (13.2) 
Understanding your 
emotions  
Psycho-education on impact on emotions  Psycho-education; Guided self-help  Information about antecedents (4.2); Information about health 
consequences (5.1); Salience of consequences (5.2); Information 
about social and environmental consequences (5.3); Information 
about emotional consequences (5.6) 
 31 
 
Shifting your focus  Attention narrowing; Attention switching; 
Emotional regulation; 
Recognize/understand/normalize emotions; 
Developing more appropriate coping 
strategies 
Coping strategy enhancement (CSE); 
Mindfulness-based cognitive therapy  
Information about emotional consequences (5.6); Behavioral 
practice/rehearsal (8.1); Reduce negative emotions (11.2); Problem 
solving (1.2); Social support (unspecified) (3.1); Behavioral 
practice/rehearsal (8.1); Distraction (12.4) 
Understanding your 
physical sensations  
Psycho-education on impact of physical 
sensations  
Psycho-education; Guided self-help  Information about antecedents (4.2); Information about health 
consequences (5.1); Salience of consequences (5.2); Information 
about social and environmental consequences (5.3); Information 
about emotional consequences (5.6) 
Surfing your cravings 
and urges 
Urge surfing; Body scanning; Relapse 
prevention-based techniques  
Mindfulness-based cognitive therapy  Instruction on how to perform a behavior (4.1); Behavioral 
practice/rehearsal (8.1); Reduce negative emotions (11.2) 
Understanding your 
unhelpful behaviors  
Psycho-education on impact of destructive 
behaviors  
Psycho-education; Guided self-help  Information about antecedents (4.2); Information about health 
consequences (5.1); Salience of consequences (5.2); Information 
about social and environmental consequences (5.3); Information 
about emotional consequences (5.6) 
Planning your time 
positively  
Activity scheduling; Behavioral activation; 
Encourage new behaviors via positive 
feedback; Increase activity to increase 
energy levels and relieve boredom 
Cognitive-behavioral therapy (CBT)  Non-specific reward (10.3); Non-specific incentive (10.6); Reward 
approximation (14.4); Rewarding completion (14.5); Goal setting 
(behavior) (1.1); Action planning (1.4) 
Understanding your 
lifestyle  
Psycho-education on impact of lifestyle; 
Creating SMART goals for recovery 
Psycho-education; Guided self-help  Goal setting (behavior) (1.1); Problem solving (1.2); Goal setting 
(outcome) (1.3); Action planning (1.4) 
Achieving your life goals  Goal-setting  
Increase treatment engagement and 
retention. Increase readiness to change 
behavior 
Motivational enhancement therapy (MET); 
Implementation intentions  
Non-specific reward (10.3); Focus on past success (15.3); Action 
planning (1.4) 
Progress check  Monitor behavior to provide feedback 
about progress towards goals; Encourage 
new behaviors via positive feedback 
Self-monitoring  Self-monitoring of behavior (2.3); Feedback on outcome(s) of 
behavior (2.7) 
Information on alcohol 
and drugs 
Psycho-education on effects of alcohol and 
drugs; Reduce negative or fatal 
consequences of substance using behaviors 
Harm reduction; Psycho-education  Information about health consequences (5.1); Salience of 





Appendix A: Additional socio-demographic questions 1 
1. What is your date of birth? 2 
 3 
2. What is your marital status? 4 
Married / civil partnership             5 
Single              6 
              Divorced / separated                            7 
              Widowed              8 
              Living with partner                            9 
 10 
3. What was your occupation before you came to prison (select more than one response if 11 
applicable)? 12 
               In full-time employment (specify)  13 
               In part-time employment (specify)      14 
               In full-time education (specify)              15 
               In part-time education (specify)          16 
               Full-time carer                            17 
               Unemployed        18 
               Other (specify)   19 
 20 
4. At what level did you finish full-time education?  21 
Primary school   22 
Secondary school  23 
Further education (i.e. course of study after secondary school level education)   24 
Higher education (i.e. undergraduate or postgraduate university course of study)  25 
No formal education  26 




Appendix B: Standard treatment questions 2 
1. Which of the following treatments for your drug or alcohol difficulties did you receive 3 
whilst during your participating in the study? 4 
Prescribed substitute medication                                                5 
Medication for detox                                                                     6 
Mental health medication e.g. antidepressants                       7 
One to one key-working                                                                8 
Structured group intervention delivered by practitioners                                                                     9 
Mutual aid group work e.g. AA, NA, SMART                             10 
Complementary therapies, e.g. acupuncture                         11 
   12 
2. What kind of practitioners have provided you with support during your participating in the 13 
study? 14 
Recovery workers/ drug workers                                           15 
Medical professional e.g. Psychiatrist, GP                            16 
Nurse/ Mental health nurse                                                   17 
Psychologist/ counsellor                                                         18 
Offender manager                                                                     19 
Listeners/ peer mentors                                                          20 
 21 
3. How often did you receive support from practitioners during your participation in the 22 
study? 23 
Every day                                                                                   24 
Several days each week  25 
One day each week                                                                26 
Several days each month Once a month                                                                           27 
 34 
 
Less than once a month                                                           1 
 2 
Appendix C: Further criminal justice system involvement questions (for participants who have 3 
been released from prison at 3- or 6-month follow-up). 4 
We would like to ask you about any involvement you may have had with criminal justice authorities 5 
since we last spoke to you. You do not have to tell us about any crimes you may have committed 6 
that are not currently being dealt with by criminal justice authorities: 7 
1. Have you been re-arrested since completing your last prison sentence? 8 
 9 
2. Have you had attended any more court appearances related to offenses you have been 10 
accused of committing since completing your last prison sentence? 11 
 12 
3. Have you been convicted of any new offences since you completed your last prison 13 
sentence? 14 
 15 
4. Have you been recalled to prison since completing your last prison sentence? 16 
 17 
 18 
